A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma
Oncologist. 2023 Nov 30:oyad310. doi: 10.1093/oncolo/oyad310. Online ahead of print.ABSTRACTHerein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of chemotherapy with cisplatin and pemetrexed, and a second line of immunotherapy with atezolizumab. Comprehensive genomic profiling by nex...
Source: The Oncologist - December 1, 2023 Category: Cancer & Oncology Authors: Marco Maria Germani Chiara Boccaccio Antonio Matrone Eleonora Molinaro Greta Al ì Mirella Giordano Rossella Elisei Gabriella Fontanini Chiara Cremolini Source Type: research

Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy
CONCLUSIONS: A subset of patients with S/R dedifferentiation derive clinical benefit from TT after they have progressive disease on ICT. Patients with R dedifferentiation appeared to derive more benefit from TT than those with S dedifferentiation.PMID:38035767 | DOI:10.1093/oncolo/oyad302 (Source: The Oncologist)
Source: The Oncologist - November 30, 2023 Category: Cancer & Oncology Authors: Andrew W Hahn Devaki Shilpa Surasi Paul V Viscuse Tharakeswara K Bathala Andrew J Wiele Matthew T Campbell Amado J Zurita Amishi Y Shah Eric Jonasch Jianjun Gao Sangeeta Goswami Omar Alhalabi Priya Rao Kanishka Sircar Nizar M Tannir Pavlos Msaouel Source Type: research

Correction to: Comparisons of Nonoral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles
Oncologist. 2023 Nov 29:oyad318. doi: 10.1093/oncolo/oyad318. Online ahead of print.NO ABSTRACTPMID:38019641 | DOI:10.1093/oncolo/oyad318 (Source: The Oncologist)
Source: The Oncologist - November 29, 2023 Category: Cancer & Oncology Source Type: research

Correction to: Comparisons of Nonoral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles
Oncologist. 2023 Nov 29:oyad318. doi: 10.1093/oncolo/oyad318. Online ahead of print.NO ABSTRACTPMID:38019641 | DOI:10.1093/oncolo/oyad318 (Source: The Oncologist)
Source: The Oncologist - November 29, 2023 Category: Cancer & Oncology Source Type: research

Trajectory of Healthcare Contact Days for Veterans With Advanced Gastrointestinal Malignancy
Oncologist. 2023 Nov 28:oyad313. doi: 10.1093/oncolo/oyad313. Online ahead of print.ABSTRACTHow and where patients with advanced cancer facing limited survival spend their time is critical. Healthcare contact days (days with healthcare contact outside the home) offer a patient-centered and practical measure of how much of a person's life is consumed by healthcare. We retrospectively analyzed contact days among decedent veterans with stage IV gastrointestinal cancer at the Minneapolis Veterans Affairs Healthcare System from 2010 to 2021. Among 468 decedents, the median overall survival was 4 months. Patients spent 1 in 3 da...
Source: The Oncologist - November 28, 2023 Category: Cancer & Oncology Authors: Whitney V Johnson Quan H Phung Vishal R Patel Alexander K Tsai Nivedita Arora Mark A Klein Anders D Westanmo Anne H Blaes Arjun Gupta Source Type: research

Trajectory of Healthcare Contact Days for Veterans With Advanced Gastrointestinal Malignancy
Oncologist. 2023 Nov 28:oyad313. doi: 10.1093/oncolo/oyad313. Online ahead of print.ABSTRACTHow and where patients with advanced cancer facing limited survival spend their time is critical. Healthcare contact days (days with healthcare contact outside the home) offer a patient-centered and practical measure of how much of a person's life is consumed by healthcare. We retrospectively analyzed contact days among decedent veterans with stage IV gastrointestinal cancer at the Minneapolis Veterans Affairs Healthcare System from 2010 to 2021. Among 468 decedents, the median overall survival was 4 months. Patients spent 1 in 3 da...
Source: The Oncologist - November 28, 2023 Category: Cancer & Oncology Authors: Whitney V Johnson Quan H Phung Vishal R Patel Alexander K Tsai Nivedita Arora Mark A Klein Anders D Westanmo Anne H Blaes Arjun Gupta Source Type: research

Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival
CONCLUSIONS: This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.PMID:38006197 | DOI:10.1093/oncolo/oyad314 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Rongzhi Wang Rhiannon D Reed Griffin Price Peter Abraham Marshall Lewis Jessica Liu McMullin Paul MacLennan Cozette Killian Jayme E Locke Song Ong Vineeta Kumar Andrea Gillis Brenessa Lindeman Herbert Chen Jessica Fazendin Source Type: research

Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments
CONCLUSION: NET patients have heterogeneous priorities when choosing between treatment options based on the results of 2 independent DCEs. These results highlight the importance of shared decision making for NET patients.PMID:38007397 | DOI:10.1093/oncolo/oyad312 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Matthew Anaka David Chan Sharon Pattison Alia Thawer Bryan Franco Lesley Moody Christopher Jackson Eva Segelov Simron Singh Source Type: research

Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer
CONCLUSION: The DPM tool demonstrated positive adoption, adherence, and user experience for patients with lung/breast cancer, suggesting that DPM tools may benefit clinical cancer care.PMID:38007400 | DOI:10.1093/oncolo/oyad289 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Edurne Arriola Jana Jaal Anne Edvardsen Maria Silvoniemi Ant ónio Araújo Anders Vikstr öm Eleni Zairi Mari Carmen Rodriguez-Mues Marco Roccato Sophie Schneider Johannes Ammann Source Type: research

Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival
CONCLUSIONS: This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.PMID:38006197 | DOI:10.1093/oncolo/oyad314 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Rongzhi Wang Rhiannon D Reed Griffin Price Peter Abraham Marshall Lewis Jessica Liu McMullin Paul MacLennan Cozette Killian Jayme E Locke Song Ong Vineeta Kumar Andrea Gillis Brenessa Lindeman Herbert Chen Jessica Fazendin Source Type: research

Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
Oncologist. 2023 Nov 24:oyad316. doi: 10.1093/oncolo/oyad316. Online ahead of print.NO ABSTRACTPMID:38000087 | DOI:10.1093/oncolo/oyad316 (Source: The Oncologist)
Source: The Oncologist - November 24, 2023 Category: Cancer & Oncology Source Type: research

Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients
CONCLUSION: Our retrospective analysis of real world palbociclib use reveals an association with grade 3/4 neutropenia with better outcome and early neutropenia nadir with worse outcome. Our findings of Asian specific SNPs support a predisposition toward profound and prevalent neutropenia in Asian patients under CDK4/6i. We also report the first pharmacokinetics analysis on a patient with peritoneal dialysis receiving CDK4/6i. In summary, our study provides novel clinical and genotypic insights into CDK4/6i associated neutropenia.PMID:37995303 | DOI:10.1093/oncolo/oyad304 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Jiun-I Lai Ting-Hao Kuo Kuan-Jung Huang Laura Min Xuan Chai Mei-Hsuan Lee Chun-Yu Liu Yi-Fang Tsai Chi-Cheng Huang Ling-Ming Tseng Cheng-Chih Hsu Ta-Chung Chao Source Type: research

Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review
CONCLUSION: The hydration scheme of cisplatin should be short and consist of a relatively small amount of volume. The scheme should include mannitol and magnesium supplementation. Head-to-head studies are needed to investigate the safety of furosemide compared with mannitol and the dose of mannitol and magnesium.PMID:37995306 | DOI:10.1093/oncolo/oyad297 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Charlotte Sikking Kelly L Niggebrugge-Mentink A S Elise van der Sman Roefke H P Smit Esther W Bouman-Wammes Marieke M Beex-Oosterhuis Charlotte van Kesteren Source Type: research

Perspectives on the Treatment of Multiple Myeloma
Oncologist. 2023 Nov 23:oyad306. doi: 10.1093/oncolo/oyad306. Online ahead of print.ABSTRACTThe treatment of multiple myeloma has evolved significantly over the past few decades with the development of novel therapeutics. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and high-dose chemotherapy followed by hematopoietic stem cell transplantation has led to improved response rates and survival outcomes. The use of bispecific antibodies and chimeric antigen receptor T-cell therapy is currently under study, and early results are showing promise. Although outcomes for patients with MM...
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Abdul Rafae Frits van Rhee Samer Al Hadidi Source Type: research

Patient-Reported Outcomes of Accelerated Aging: A Novel Approach to Investigate Second Cancer Risk in Adolescent and Young Adult (18-39 Years) Cancer Survivors
CONCLUSION: AYAs with a higher burden of accelerated aging were more likely to develop a second cancer. Validation of the clinical indicators and how to best capture them is needed to improve (early) detection of AYAs at high risk of developing second cancer.PMID:37995309 | DOI:10.1093/oncolo/oyad307 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Dani ël J van der Meer Susan Zevenbergen Carla Vlooswijk Rhod é M Bijlsma Suzanne E J Kaal Jan Martijn Kerst Jacqueline M Tromp Monique E M M Bos Tom van der Hulle Roy I Lalisang Janine Nuver Mathilde C M Kouwenhoven Winette T A van der Graaf Olga Husso Source Type: research